Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2012

View Archived Issues

New S1P1 receptor agonists prepared by Allergan

Novel PI3K-alpha/mTORC1 inhibitors disclosed by Exelixis

Phase III study planned for MOD-4023

Novo Nordisk presents new long-acting drug for growth hormone deficiency

Lilly diabetes drug substantially decreases HbA1c without delaying recovery from hypoglycemia

Amicus reports preliminary results from phase II study in Pompe's disease

AstraZeneca patents novel agents for arrhythmia

Novel TRPV1 channel antagonists developed at GlaxoSmithKline

Polish team describes new fusion proteins for cancer

Korean researchers present novel protein kinase inhibitors

Merck KGaA designs new hPDK1 inhibitors

New fusion proteins for bone disorders designed in Korea

Research collaboration begins for Parkinson's disease gene therapy

EMA issues scientific opinion on Sanofi Pasteur vaccine

QRxPharma receives complete response letter for MoxDuo

Topica launches phase IIb/III study in onychomycosis

Dosing begins in first-in-human PA-401 trial

New gevokizumab trials initiated in uveitis and erosive osteoarthritis

FDA issues safety communication on cefepime

Depomed acquires rights to liquid-filled capsule analgesic

FDA approves first new weight loss drug in 13 years

Sunesis Pharmaceuticals receives milestone payment for kinase inhibitor program

PTC Therapeutics begins open-label ataluren study

FDA grants premarket approval to noninvasive test to detect prostate cancer

Janssen-Cilag applies for European approval of canagliflozin

CHMP issues opinion on Zyclara MAA

FDA issues complete response letter for Xarelto sNDA

Favorable preclinical profile supports clinical testing of grass pollen vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...